Premium
Effects of clomiphene citrate on endometrial hyperplasia in the premenopausal female
Author(s) -
Kistner Robert W.,
Lewis John L.,
Steiner Gillen J.
Publication year - 1966
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196601)19:1<115::aid-cncr2820190113>3.0.co;2-f
Subject(s) - medicine , endometrial hyperplasia , follicular phase , endometrium , ovulation , menopause , gynecology , hyperplasia , ovary , clomifene , atrophy , hysterectomy , estrogen , hormone , ovulation induction , surgery
Clomiphene was administered continuously in a dose of 100 to 200 mg daily for 16 to 18 months to 6 patients (5 approaching menopause and one postmenopausal) having endometrial hyperplasia with a presenting complaint of irregular and profuse bleeding. After cessation of clomiphene therapy the results were atypical secretory endometrium—2 patients; normal menstrual cycles—3 patients; spontaneous menopause—one patient. The therapeutic effects of clomiphene are temporary. If the ovary maintains its potential for follicular maturation and ovulation, a secretory phase will be induced in the endometrium which lasts 6 to 8 weeks. Endometrial atrophy then will develop and remain unchanged as long as therapy is continued. The major side effects of clomiphene are hot flashes and ovarian cysts.